1921
Volume 96, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

antibiotic susceptibility in the Dominican Republic has not been monitored. We assessed antibiotic susceptibility in the Dominican Republic, and analyzed mutations associated with antibiotic resistance. We recruited 158 dyspeptic patients in Santo Domingo and used agar dilution to test susceptibility to five antibiotics. Polymerase chain reaction–based sequencing was used to assess , , , , and 23S rRNA mutations; next-generation sequencing was used to identify other metronidazole resistance–associated genes. Among 64 strains isolated, we identified two (3.1%), one (1.6%), and no strains with clarithromycin, amoxicillin, and tetracycline resistance, respectively. Moreover, high frequency of metronidazole resistance (53/64, 82.8%) was observed, whereas levofloxacin resistance is emerging (23/64, 35.9%). We identified many and mutations in metronidazole-resistant strains, but no synergistic effect was apparent. We revealed novel mutations in , , , and , irrespective of and mutations. Novel mutations at Ser-14 of and Arg-221 of were associated with different levels of metronidazole resistance. Most levofloxacin-resistant strains had a substitution at Asn-87 of , including the strain with the highest levofloxacin resistance, whereas only three substitutions were found at Ser-479 of with no synergistic effect. Besides the 23S rRNA A2142G mutation, we observed another mutation at T1958G in both clarithromycin-resistant strains. We confirmed high metronidazole and levofloxacin resistance associated with genetic mutations in the Dominican Republic. However, prevalence of clarithromycin resistance was low, suggesting that standard clarithromycin-based triple therapy remains useful as initial treatment of infection.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.16-0729
2017-02-13
2019-05-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/96/5/1050.html?itemId=/content/journals/10.4269/ajtmh.16-0729&mimeType=html&fmt=ahah

References

  1. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA, , 2009. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 24: 15871600.[Crossref] [Google Scholar]
  2. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, European Helicobacter Study Group; , 2012. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report. Gut 61: 646664.[Crossref] [Google Scholar]
  3. Papastergiou V, Georgopoulos SD, Karatapanis S, , 2014. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol 20: 98989911.[Crossref] [Google Scholar]
  4. Miftahussurur M, Yamaoka Y, , 2015. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules 20: 60686092.[Crossref] [Google Scholar]
  5. Suzuki RB, Lopes RA, da Camara Lopes GA, Hung Ho T, Speranca MA, , 2013. Low Helicobacter pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of Sao Paulo, Brazil. BMC Gastroenterol 13: 164.[Crossref] [Google Scholar]
  6. Stone GG, Shortridge D, Flamm RK, Versalovic J, Beyer J, Idler K, Zulawinski L, Tanaka SK, , 1996. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori . Helicobacter 1: 227228.[Crossref] [Google Scholar]
  7. Goodwin A, Kersulyte D, Sisson G, Veldhuyzen van Zanten SJ, Berg DE, Hoffman PS, , 1998. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol 28: 383393.[Crossref] [Google Scholar]
  8. Jeong JY, Mukhopadhyay AK, Dailidiene D, Wang Y, Velapatino B, Gilman RH, Parkinson AJ, Nair GB, Wong BC, Lam SK, Mistry R, Segal I, Yuan Y, Gao H, Alarcon T, Brea ML, Ito Y, Kersulyte D, Lee HK, Gong Y, Goodwin A, Hoffman PS, Berg DE, , 2000. Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level metronidazole resistance in Helicobacter pylori . J Bacteriol 182: 50825090.[Crossref] [Google Scholar]
  9. Binh TT, Suzuki R, Trang TT, Kwon DH, Yamaoka Y, , 2015. Search for novel candidate mutations for metronidazole resistance in Helicobacter pylori using next-generation sequencing. Antimicrob Agents Chemother 59: 23432348.[Crossref] [Google Scholar]
  10. Li AQ, Dai N, Yan J, Zhu YL, , 2007. Screening for metronidazole-resistance associated gene fragments of H. pylori by suppression subtractive hybridization. World J Gastroenterol 13: 18471850.[Crossref] [Google Scholar]
  11. Chang KC, Ho SW, Yang JC, Wang JT, , 1997. Isolation of a genetic locus associated with metronidazole resistance in Helicobacter pylori . Biochem Biophys Res Commun 236: 785788.[Crossref] [Google Scholar]
  12. Mukhopadhyay AK, Jeong JY, Dailidiene D, Hoffman PS, Berg DE, , 2003. The fdxA ferredoxin gene can down-regulate frxA nitroreductase gene expression and is essential in many strains of Helicobacter pylori . J Bacteriol 185: 29272935.[Crossref] [Google Scholar]
  13. Kwon DH, El-Zaatari FA, Kato M, Osato MS, Reddy R, Yamaoka Y, Graham DY, , 2000. Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori . Antimicrob Agents Chemother 44: 21332142.[Crossref] [Google Scholar]
  14. Baker LM, Raudonikiene A, Hoffman PS, Poole LB, , 2001. Essential thioredoxin-dependent peroxiredoxin system from Helicobacter pylori: genetic and kinetic characterization. J Bacteriol 183: 19611973.[Crossref] [Google Scholar]
  15. Jones KR, Cha JH, Merrell DS, , 2008. Who's winning the war? Molecular mechanisms of antibiotic resistance in Helicobacter pylori . Curr Drug Ther 3: 190203.[Crossref] [Google Scholar]
  16. Rimbara E, Noguchi N, Kawai T, Sasatsu M, , 2012. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB . Helicobacter 17: 3642.[Crossref] [Google Scholar]
  17. Camargo MC, Garcia A, Riquelme A, Otero W, Camargo CA, Hernandez-Garcia T, Candia R, Bruce MG, Rabkin CS, , 2014. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 109: 485495.[Crossref] [Google Scholar]
  18. Shiota S, Cruz M, Abreu JA, Mitsui T, Terao H, Disla M, Iwatani S, Nagashima H, Matsuda M, Uchida T, Tronilo L, Rodriguez E, Yamaoka Y, , 2014. Virulence genes of Helicobacter pylori in the Dominican Republic. J Med Microbiol 63: 11891196.[Crossref] [Google Scholar]
  19. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ, , 2007. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56: 772781.[Crossref] [Google Scholar]
  20. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM, European Helicobacter and Microbiota Study Group and Consensus Panel; , 2017. Management of Helicobacter pylori infection: the Maastricht V/Florence Consensus Report. Gut 66: 630.[Crossref] [Google Scholar]
  21. Kwon DH, Pena JA, Osato MS, Fox JG, Graham DY, Versalovic J, , 2000. Frameshift mutations in rdxA and metronidazole resistance in North American Helicobacter pylori isolates. J Antimicrob Chemother 46: 793796.[Crossref] [Google Scholar]
  22. Wang LH, Cheng H, Hu FL, Li J, , 2010. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol 16: 22722277.[Crossref] [Google Scholar]
  23. Ho SL, Tan EL, Sam CK, Goh KL, , 2010. Clarithromycin resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Malaysia. J Dig Dis 11: 101105.[Crossref] [Google Scholar]
  24. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A, , 2010. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 19: 409414. [Google Scholar]
  25. Martinez-Julvez M, Rojas AL, Olekhnovich I, Espinosa Angarica V, Hoffman PS, Sancho J, , 2012. Structure of RdxA: an oxygen-insensitive nitroreductase essential for metronidazole activation in Helicobacter pylori . FEBS J 279: 43064317.[Crossref] [Google Scholar]
  26. Jenks PJ, Ferrero RL, Labigne A, , 1999. The role of the rdxA gene in the evolution of metronidazole resistance in Helicobacter pylori . J Antimicrob Chemother 43: 753758.[Crossref] [Google Scholar]
  27. Kwon DH, Hulten K, Kato M, Kim JJ, Lee M, El-Zaatari FA, Osato MS, Graham DY, , 2001. DNA sequence analysis of rdxA and frxA from 12 pairs of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates. Antimicrob Agents Chemother 45: 26092615.[Crossref] [Google Scholar]
  28. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y, Study Group Participants; , 2013. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62: 3442.[Crossref] [Google Scholar]
  29. Boyanova L, Mitov I, , 2010. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 8: 5970.[Crossref] [Google Scholar]
  30. Wirtz VJ, Dreser A, Gonzales R, , 2010. Trends in antibiotic utilization in eight Latin American countries, 1997–2007. Rev Panam Salud Publica 27: 219225.[Crossref] [Google Scholar]
  31. Oleastro M, Ménard A, Santos A, Lamouliatte H, Monteiro L, Barthélémy P, Mégraud F, , 2003. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori . J Clin Microbiol 41: 397402.[Crossref] [Google Scholar]
  32. Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M, , 2013. How antibiotic resistances could change Helicobacter pylori treatment: a matter of geography? World J Gastroenterol 19: 81688180.[Crossref] [Google Scholar]
  33. De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, Stella F, Di Leo A, Russo F, Marangi S, Monno R, Stoppino V, Morini S, Panella C, Ierardi E, , 2006. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori . Ann Intern Med 144: 94100.[Crossref] [Google Scholar]
  34. Dore MP, Osato MS, Realdi G, Mura I, Graham DY, Sepulveda AR, , 1999. Amoxycillin tolerance in Helicobacter pylori . J Antimicrob Chemother 43: 4754.[Crossref] [Google Scholar]
  35. Yakoob J, Fan X, Hu G, Liu L, Zhang Z, , 2001. Antibiotic susceptibility of Helicobacter pylori in the Chinese population. J Gastroenterol Hepatol 16: 981985.[Crossref] [Google Scholar]
  36. Hu CT, Wu CC, Lin CY, Cheng CC, Su SC, Tseng YH, Lin NT, , 2007. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J Gastroenterol Hepatol 22: 720723. [Google Scholar]
  37. Kim N, Kim JM, Kim CH, Park YS, Lee DH, Kim JS, Jung HC, Song IS, , 2006. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol 40: 683687.[Crossref] [Google Scholar]
  38. Megraud F, , 2004. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53: 13741384.[Crossref] [Google Scholar]
  39. Farshad S, Alborzi A, Japoni A, Ranjbar R, Hosseini Asl K, Badiee P, Amin Shahidi M, Hosseini M, , 2010. Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, southern Iran. World J Gastroenterol 16: 57465751.[Crossref] [Google Scholar]
  40. Malfertheiner P, Bazzoli F, Delchier JC, Celinski K, Giguere M, Riviere M, Megraud F, Pylera Study Group; , 2011. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 377: 905913.[Crossref] [Google Scholar]
  41. Teh X, Khosravi Y, Lee WC, Leow AH, Loke MF, Vadivelu J, Goh KL, , 2014. Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur. PLoS One 9: e101481.[Crossref] [Google Scholar]
  42. Richaud C, Higgins W, Mengin-Lecreulx D, Stragier P, , 1987. Molecular cloning, characterization, and chromosomal localization of dapF, the Escherichia coli gene for diaminopimelate epimerase. J Bacteriol 169: 14541459.[Crossref] [Google Scholar]
  43. Trend MA, Jorgensen MA, Hazell SL, Mendz GL, , 2001. Oxidases and reductases are involved in metronidazole sensitivity in Helicobacter pylori . Int J Biochem Cell Biol 33: 143153.[Crossref] [Google Scholar]
  44. Gisbert JP, Gonzalez L, Calvet X, , 2005. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter 10: 157171.[Crossref] [Google Scholar]
  45. Gisbert JP, , 2009. Second-line rescue therapy of Helicobacter pylori infection. Therap Adv Gastroenterol 2: 331356.[Crossref] [Google Scholar]
  46. Andrade SS, Sader HS, Jones RN, Pereira AS, Pignatari AC, Gales AC, , 2006. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines? Mem Inst Oswaldo Cruz 101: 741748. [Google Scholar]
  47. Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology; , 2007. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102: 18081825.[Crossref] [Google Scholar]
  48. Nishizawa T, Suzuki H, Kurabayashi K, Masaoka T, Muraoka H, Mori M, Iwasaki E, Kobayashi I, Hibi T, , 2006. Gatifloxacin resistance and mutations in gyrA after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob Agents Chemother 50: 15381540.[Crossref] [Google Scholar]
  49. Garcia M, Raymond J, Garnier M, Cremniter J, Burucoa C, , 2012. Distribution of spontaneous gyrA mutations in 97 fluoroquinolone-resistant Helicobacter pylori isolates collected in France. Antimicrob Agents Chemother 56: 550551.[Crossref] [Google Scholar]
  50. Sugimoto M, Furuta T, , 2014. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol 20: 64006411.[Crossref] [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0729
Loading
/content/journals/10.4269/ajtmh.16-0729
Loading

Data & Media loading...

  • Received : 08 Sep 2016
  • Accepted : 16 Dec 2016
  • Published online : 13 Feb 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error